BRNS Barinthus Biotherapeutics plc.

Nasdaq www.barinthusbio.com


$ 1.31 $ 0.04 (3.1 %)    

Friday, 24-Oct-2025 16:16:22 EDT
QQQ $ 617.50 $ 6.52 (1.07 %)
DIA $ 472.45 $ 4.92 (1.05 %)
SPY $ 677.25 $ 5.49 (0.82 %)
TLT $ 91.47 $ 0.04 (0.04 %)
GLD $ 378.59 $ -1.27 (-0.34 %)
$ 1.33
$ 1.29
$ 1.20 x 1,967
$ 1.38 x 111
$ 1.20 - $ 1.38
$ 0.64 - $ 2.92
58,360
na
54.16M
$ 0.78
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-07-2025 03-31-2025 10-Q
3 03-20-2025 12-31-2024 10-K
4 11-06-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
7 03-20-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-12-2023 03-31-2023 10-Q
11 03-24-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-09-2022 06-30-2022 10-Q
14 05-11-2022 03-31-2022 10-Q
15 03-25-2022 12-31-2021 10-K
16 11-12-2021 09-30-2021 10-Q
17 08-12-2021 06-30-2021 10-Q
18 06-14-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 chemdiv-to-continue-rd-support-as-clywedog-merges-with-barinthus-therapeutics-combined-entity-to-trade-under-ticker-clyd-on-nasdaq

ChemDiv, a global provider of integrated drug discovery solutions, today announced that it will continue providing chemistry, c...

 barinthus-biotherapeutics-and-clywedog-therapeutics-enters-into-a-definitive-all-stock-merger-agreement-to-form-combined-company-before-transaction-closes-the-combined-company-may-initiate-partial-tender-offer-to-purchase-up-to-27m-worth-of-its-outstanding-shares-held-by-barinthus-bio-shareholders

Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio"), an immunology and inflammation company focused on develo...

 barinthus-biotherapeutics-q2-eps-052-misses-033-estimate

Barinthus Biotherapeutics (NASDAQ:BRNS) reported quarterly losses of $(0.52) per share which missed the analyst consensus estim...

 barinthus-biotherapeutics-q1-eps-049-misses-036-estimate

Barinthus Biotherapeutics (NASDAQ:BRNS) reported quarterly losses of $(0.49) per share which missed the analyst consensus estim...

 hc-wainwright--co-reiterates-buy-on-barinthus-biotherapeutics-maintains-3-price-target

HC Wainwright & Co. analyst Yi Chen reiterates Barinthus Biotherapeutics (NASDAQ:BRNS) with a Buy and maintains $3 price...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION